Use of serum uPA change to predict PFS and overall survival in first-line trastuzumab-treated breast cancer

被引：0
|
作者：
Hou, H. Y.
Anyanwu, U.
Jamshidi, N.
Leitzel, K.
Ali, S. M.
Koestler, W.
Fuchs, E.
Hamer, P.
Carney, W. P.
Lipton, A.
机构：
[1] Penn State Hershey Med Ctr, Hershey, PA USA
[2] Lebanon VA Med Ctr, Lebanon, PA USA
[3] Med Univ Vienna, Vienna, Austria
[4] Siemens Healthcare Diagnost, Cambridge, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.1050
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1050
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Progression-free survival (PFS) as a surrogate end point for overall survival (OS) in first-line treatment of advanced epithelial ovarian cancer (EOC).
    Sjoquist, Katrin Marie
    Lee, Chee
    Lord, Sally
    Chatfield, Mark D.
    Friedlander, Michael
    Simes, John
    Marschner, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [22] Overall survival in Japanese patients with ER+/HER2− advanced breast cancer treated with first-line palbociclib plus letrozole
    Masato Takahashi
    Tomofumi Osako
    Hiroyuki Yasojima
    Kenichi Inoue
    Masahiro Kawashima
    Hideki Maeda
    Akemi Ichikawa
    Yasuaki Muramatsu
    Norikazu Masuda
    Breast Cancer, 2024, 31 : 53 - 62
  • [23] Overall survival in Japanese patients with ER+/HER2-advanced breast cancer treated with first-line palbociclib plus letrozole
    Takahashi, Masato
    Osako, Tomofumi
    Yasojima, Hiroyuki
    Inoue, Kenichi
    Kawashima, Masahiro
    Maeda, Hideki
    Ichikawa, Akemi
    Muramatsu, Yasuaki
    Masuda, Norikazu
    BREAST CANCER, 2024, 31 (01) : 53 - 62
  • [24] SERUM HER2ECD LEVELS IN PATIENTS WITH ADVANCED GASTRIC CANCER TREATED WITH TRASTUZUMAB AS FIRST-LINE THERAPY
    Takahashi, M.
    Takahashi, Y.
    Ohori, H.
    Gamoh, M.
    ANNALS OF ONCOLOGY, 2013, 24
  • [25] Evaluation of two-dimensional response to predict overall survival in patients with metastatic colorectal cancer treated with the first-line bevacizumab-based chemotherapy
    Nakayama, Goro
    Takano, Nao
    Tanaka, Chie
    Kobayashi, Daisuke
    Koike, Masahiko
    Fujiwara, Michitaka
    Kodera, Yasuhiro
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [26] Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
    Marie-Laure Tanguy
    Luc Cabel
    Fréderique Berger
    Jean-Yves Pierga
    Alexia Savignoni
    Francois-Clement Bidard
    npj Breast Cancer, 4
  • [27] Cdk4/6 inhibitors and overall survival: power of first-line trials in metastatic breast cancer
    Tanguy, Marie-Laure
    Cabel, Luc
    Berger, Frederique
    Pierga, Jean-Yves
    Savignoni, Alexia
    Bidard, Francois-Clement
    NPJ BREAST CANCER, 2018, 4
  • [28] Longitudinal changes in serum her-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients
    Pichon, M.
    Bethune-Volters, A.
    Labroquere, M.
    Guepratte, S.
    Hacene, K.
    Neumann, R.
    Carney, W.
    EJC SUPPLEMENTS, 2004, 2 (03): : 138 - 139
  • [29] Longitudinal changes in serum HER-2/neu oncoprotein levels in trastuzumab-treated metastatic breast cancer patients
    Bethune-Volters, A
    Labroquere, M
    Guepratte, S
    Hacene, K
    Neumann, R
    Carney, W
    Pichon, MF
    ANTICANCER RESEARCH, 2004, 24 (2C) : 1083 - 1089
  • [30] Everolimus plus trastuzumab and paclitaxel as first-line therapy in women with HER2+advanced breast cancer: Overall survival results from BOLERO-1
    Yardley, D.
    Hurvitz, S.
    Jiang, Z-F
    Toi, M.
    Burris, H.
    Buyse, M.
    Slamon, D.
    Makhson, A.
    Elsaid, A.
    Lerzo, G.
    Hellerstedt, B.
    Nuzzo, F.
    Sohn, J.
    Manzyuk, L.
    Cabaribere, D.
    Lincy, J.
    Weimann, A.
    Noel-Baron, F.
    Pacaud, L.
    Andre, F.
    CANCER RESEARCH, 2017, 77
12345